1. Report 50, Prescribing, recording and reporting photon beam therapy. Bethesda, MD: ICRU, 1993.
2. Report 62: Supplement to ICRU report 50 prescribing, recording and reporting photon beam therapy. Bethesda, MD: ICRU, 1999.
3. Report No 58: Dose and volume specification for reporting interstitial therapy. Bethesda, MD: ICRU, 1998.
4. Gokhan, K, Rao, G, Warren, D et al. A Supervised Learning Tool for Prostate Cancer Foci Detection and Aggressiveness Identification using Multiparametric magnetic resonance imaging/magnetic resonance spectroscopy imaging. Concer Inform 2018; 17: 1–8.
5. American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society, 2017.
6. Kihlén, B, Ruden, B L. Reproducibility of field alignment in radiation therapy. A large scale clinical experience. Acta Oncol 1989; 28: 689–692.
7. Ramiandrisoa, F, Duvergé, L, Castellib, J, Nguyena, T D, Servagi-Vernat, S, De Crevoisier, R. Clinical to planning target volume margins in prostate cancer radiotherapy. Cancer Radiother 2016; 20 (6–7): 629–639.
8. Richards, M J S, Buchler, D A. Errors in reproducing pelvic radiation portals. Int J Radiat Oncol Biol Phys 1977; 2: 1017–1019.
9. IAEA-TECDOC-1540. Specification and Acceptance Testing of Radiotherapy Treatment Planning Systems. Vienna: International Atomic Energy Agency, 2007.
10. Technical Reports Series No. 430. Commissioning and Quality Assurance of Computerized Planning Systems for Radiation Treatment of Cancer. Vienna: International Atomic Energy Agency, 2004.
11. IAEA TRS-398. Absorbed Dose Determination in External Beam Radiotherapy: An International Code of Practice for Dosimetry based on Standards of Absorbed Dose to Water. Vienna, Austria: International Atomic Energy Agency, 2004.
12. Klein, E E, Hanley, J, Bayouth, J et al. AAPM Task Group 142 Report: quality assurance of medical accelerators. Med Phys 2009; 36: 4197–4212.
13. Aubry, J F, Beaulieu, L, Girouard, L M et al. Measurements of intrafraction motion and interfraction and intrafraction rotation of prostate by three-dimensional analysis of daily portal imaging with radiopaque markers. Int J Radiat Oncol Biol Phys 2004; 60: 30–39.
14. De Boer, H C J, Van Os, M J H, Jansen, P P, Heijmen, B J M. Application of the NoAction Level (NAL) protocol to correct for prostate motion based on electronicportal imaging of implanted markers. Int J Radiat Oncol Biol Phys 2005; 61: 969–983.
15. Gordon, J J, Siebers, J V. Evaluation of dosimetric margins in prostate IMRT treatment plans. Med Phys 2008; 35 (2): 569–575.
16. Bel, A, Van Herk, M, Bartelink, H, Lebesque, J V. A verification procedure to improve patient set-up accuracy using portal images. Radiother Oncol 1993; 29: 253–260.
17. Wang, K K-H, Vapiwala, N, Bui, V et al. The impact of stool and gas volume on intrafraction prostate motion in patients undergoing radiotherapy with daily endorectal balloon. Radiother Oncol 2014; 112: 89–94.
18. Huijun, Xu, Gordon, J J, Siebers, J V. Coverage-based treatment planning to accommodate delineation uncertainties in prostate cancer treatment. Med Phys. 2015; 42 (9): 5435–5443.
19. Jin, S L, Mu-Han, L, Mark, K B, Eric, M H, Chang-Ming, M. Reduction of prostate intrafractional motion from shortening the treatment time. Phys Med Biol 2013; 58 (14): 4921–4932.
20. Buettner, F, Gulliford, S L, Webb, S, Partridge, M. Using Bayesian logistic regression to evaluate a new type of dosimetric constraint for prostate radiotherapy treatment planning. Med Phys 2010; 37 (4): 1768–1777.
21. Rudat, V, Nour, A, Hammoud, M, Alaradi, A, Mohammed, A. Image-guided intensity-modulated radiotherapy of prostate cancer: analysis of interfrac-tional errors and acute toxicity. Strahlenther Onkol 2016; 192: 109–117.
22. Schallenkamp, J M, Herman, M G, Kruse, J J, Pisansky, T M. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 2005; 63: 800–811.